Tsona A, Metallidis S, Foroglou N, Selviaridis P, Chrysanthidis T, Lazaraki G, Papaioannou M, Nikolaidis J, Nikolaidis P
1st Internal Medicine Department, Infectiouse Diseases Division, AHEPA Universoty Hospital, Thessaloniki, Greece.
J Chemother. 2010 Feb;22(1):17-9. doi: 10.1179/joc.2010.22.1.17.
The aim of the study was to evaluate the penetration of linezolid into cerebrospinal fluid (CSF) and brain tissue after a single i.v. dose of 600 mg. The penetration of linezolid into cerebrospinal fluid and brain tissue was studied in 18 patients undergoing a neurosurgical procedure. Linezolid 600 mg i.v. was given with the induction of anesthesia. Mean concentrations of linezolid 2h after the final dose, in serum, cerbrospinal fluid and brain tissue were assayed by HPLC. CSF/serum and brain/serum ratios were 69.57% and 44.66% respectively. Concentrations of linezolid were above the MIC(90s )for staphylococci and streptococci. The concentrations obtained indicate good penetration of linezolid into CSF and brain tissue and support its use in the management of multidrug-resistant Gram-positive CNS infections.
本研究的目的是评估单次静脉注射600毫克利奈唑胺后其在脑脊液（CSF）和脑组织中的渗透情况。在18例接受神经外科手术的患者中研究了利奈唑胺在脑脊液和脑组织中的渗透情况。静脉注射600毫克利奈唑胺，于麻醉诱导时给药。末次给药2小时后，采用高效液相色谱法测定血清、脑脊液和脑组织中利奈唑胺的平均浓度。脑脊液/血清和脑组织/血清的比值分别为69.57%和44.66%。利奈唑胺的浓度高于葡萄球菌和链球菌的MIC（90s）。所获得的浓度表明利奈唑胺在脑脊液和脑组织中有良好的渗透性，并支持其用于耐多药革兰氏阳性中枢神经系统感染的治疗。
